Literature DB >> 22896655

Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Daniel E Bauer1, Chelsey M Mitchell, Kelly M Strait, Christopher S Lathan, Edward B Stelow, Sonja C Lüer, Somala Muhammed, Andrew G Evans, Lynette M Sholl, Juan Rosai, Eugenia Giraldi, Richard P Oakley, Carlos Rodriguez-Galindo, Wendy B London, Stephen E Sallan, James E Bradner, Christopher A French.   

Abstract

PURPOSE: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer characterized by rearrangement of the NUT gene. Research advances have provided opportunities for targeted therapy in NMC, yet the clinical features of this rare disease have not been systematically characterized. We report on a large population of such patients to identify the disease characteristics and treatments, correlate them with outcome, and to consider clinical recommendations. EXPERIMENTAL
DESIGN: A clinical database was established using retrospective demographic and outcomes data available on all known cases of NMC. Questionnaires were completed by treating physicians. Pathologic, demographic, and clinical variables were assessed for 63 patients, the largest cohort of patients with NMC studied to date. Outcome data from 54 patients were available for survival analyses.
RESULTS: The diagnosis of NMC has increased annually since 2007. Since 2009, there has been an observed increase in the age at diagnosis (P < 0.05). Geographic distribution of patients with NMC has been concentrated in the United States (n = 41, 65%). The median overall survival for patients with NMC was 6.7 months. The 2-year progression-free survival (PFS) was 9% with a 95% confidence interval (CI) of 1% to 17% [1-year PFS 15% (5-24%) and 2-year overall survival (OS) was 19% with a 95% CI of 7%-31% (1-year OS: 30% (27-34%)]. Multivariate analysis suggested that extent of surgical resection and initial radiotherapy were independent predictors of PFS and OS. Notably, no chemotherapeutic regimen was associated with improved outcome.
CONCLUSIONS: NMC portends a poor prognosis among all squamous cell neoplasms and seems to be frequently unrecognized. The finding that conventional chemotherapy has been inadequate indicates a pressing need for the development of targeted therapeutics. Intensive local therapies such as gross total resection and radiotherapy might be associated with enhanced survival. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896655      PMCID: PMC3473162          DOI: 10.1158/1078-0432.CCR-12-1153

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.

Authors:  T P Dang; A F Gazdar; A K Virmani; T Sepetavec; K R Hande; J D Minna; J R Roberts; D P Carbone
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

2.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).

Authors:  C A French; I Miyoshi; J C Aster; I Kubonishi; T G Kroll; P Dal Cin; S O Vargas; A R Perez-Atayde; J A Fletcher
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma.

Authors:  I Kubonishi; N Takehara; J Iwata; H Sonobe; Y Ohtsuki; T Abe; I Miyoshi
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

4.  Midline carcinoma of children and young adults with NUT rearrangement.

Authors:  Christopher A French; Jeffery L Kutok; William C Faquin; Jeffrey A Toretsky; Cristina R Antonescu; Constance A Griffin; Vania Nose; Sara O Vargas; Mary Moschovi; Fotini Tzortzatou-Stathopoulou; Isao Miyoshi; Antonio R Perez-Atayde; Jon C Aster; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

5.  Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19).

Authors:  U R Kees; M T Mulcahy; M L Willoughby
Journal:  Am J Pediatr Hematol Oncol       Date:  1991

6.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors:  Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

Review 7.  Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome.

Authors:  A C Lee; Y I Kwong; K H Fu; G C Chan; L Ma; Y L Lau
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

Review 8.  Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients.

Authors:  Jeffrey A Toretsky; James Jenson; Chen-Chih Sun; Allen E Eskenazi; Andrew Campbell; Stephen P Hunger; Aimee Caires; Christopher Frantz; J Laurance Hill; Judith Stamberg
Journal:  Am J Clin Oncol       Date:  2003-06       Impact factor: 2.339

Review 9.  NUT midline carcinoma: case report and review of the literature.

Authors:  Min-Shu Hsieh; Christopher A French; Cher-Wei Liang; Cheng-Hsiang Hsiao
Journal:  Int J Surg Pathol       Date:  2009-12-24       Impact factor: 1.271

10.  The role of chromosomal translocation (15;19) in the carcinoma of the upper aerodigestive tract in children.

Authors:  Reza Rahbar; Sara O Vargas; Christopher R Miyamoto; Antonio R Perez-Atayde; Christopher A French; Caroline D Robson; Greg R Licameli; Jonathan A Fletcher; Karen C Marcus; Holcombe E Grier; Trevor J McGill; Gerald B Healy
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more
  109 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  NUT midline carcinoma as a primary lung tumor: a case report.

Authors:  Jiashun Cao; Donghong Chen; Fan Yang; Jingjing Yao; Weipeng Zhu; Chuanduo Zhao
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies.

Authors:  Inga-Marie Schaefer; Paola Dal Cin; Latrice M Landry; Christopher D M Fletcher; Glenn J Hanna; Christopher A French
Journal:  Genes Chromosomes Cancer       Date:  2018-08-14       Impact factor: 5.006

4.  HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.

Authors:  Gonçalo Esteves; Joana Ferreira; Rita Afonso; Carmo Martins; Carlos Zagalo; Ana Félix
Journal:  Head Neck Pathol       Date:  2020-01-27

5.  Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations.

Authors:  Lynette M Sholl; Mizuki Nishino; Saraswati Pokharel; Mari Mino-Kenudson; Christopher A French; Pasi A Janne; Christopher Lathan
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

6.  Salivary Gland NUT Carcinoma with Prolonged Survival in Children: Case Illustration and Systematic Review of Literature.

Authors:  Huiying Wang; Vivian L Weiss; Robert D Hoffman; Ty Abel; Richard H Ho; Scott C Borinstein; Kyle Mannion; Julia A Bridge; Jennifer Black; Jiancong Liang
Journal:  Head Neck Pathol       Date:  2020-02-19

7.  NUT midline carcinoma in the right orbit: a case report.

Authors:  Tingting Ding; Yajin Wang; Tai Zhao; Zhoumin Xu; Wenwen Gao; Zhangli Cui; Yuqing Du
Journal:  Cancer Biol Ther       Date:  2019-04-16       Impact factor: 4.742

8.  Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Authors:  Takeshi Shimamura; Zhao Chen; Margaret Soucheray; Julian Carretero; Eiki Kikuchi; Jeremy H Tchaicha; Yandi Gao; Katherine A Cheng; Travis J Cohoon; Jun Qi; Esra Akbay; Alec C Kimmelman; Andrew L Kung; James E Bradner; Kwok-Kin Wong
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

9.  NUT Midline Carcinoma of the Nasal Cavity.

Authors:  Mia Edgar; Andria M Caruso; Esther Kim; Robert D Foss
Journal:  Head Neck Pathol       Date:  2016-10-18

10.  Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Authors:  Anastasios Stathis; Emanuele Zucca; Mohamed Bekradda; Carlos Gomez-Roca; Jean-Pierre Delord; Thibault de La Motte Rouge; Emmanuelle Uro-Coste; Filippo de Braud; Giuseppe Pelosi; Christopher A French
Journal:  Cancer Discov       Date:  2016-03-14       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.